Compare Eli Lilly And Co (LLY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Thomson Reuters Corp — how do they compare? Eli Lilly And Co trades at $1,159.35 (market cap $1.02T), while Thomson Reuters Corp trades at $93.21 (market cap $41.28B). The key difference: Eli Lilly And Co is far larger — about 24.7× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| LLY | TRI | |
|---|---|---|
Market Cap | $1.02T | $41.28B |
Sector | Health | Industrials |
52-Week High | $1.24K | $205.54 |
52-Week Low | $625.65 | $76.55 |
Enterprise Value | $1.06T | $43.24B |
Dividend Yield | 0.6% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Thomson Reuters (TRI) trades at $95.43, down 0.8% today, with a bullish technical signal and strong analyst consensus. The stock shows robust profitability with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent corporate actions include a special dividend and a reverse stock split, while news highlights AI integration and a joint venture with KKR.
Outlook is positive with a consensus price target of $129.96 implying 36% upside, supported by solid cash flow and debt reduction. Risks include execution of AI strategy and competitive pressures. Wall Street sentiment is bullish with 52% buy ratings, but investors should monitor Q2 2026 earnings due August 5 for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
